StockWatch
·

Parmax Pharma Ltd Q3 FY25 Results

PARMAXQ3 FY25 Results
Filing
MetricValue ( Cr)vs Q2 FY25
Revenue6.2832.3%
Total Income6.3033.0%
Expenditure6.6930.4%
PBT-0.4082.0%
Net Profit-0.4082.0%
OPM-14.69%5.36pp
NPM-6.27%3.96pp
EPS-1.0581.0%
View full financials

Informational and educational content only. Not investment advice.